Changes in diabetes prevalence and corresponding risk factors - findings from 3- and 6-year follow-up of PURE Poland cohort study.
Adult
Aged
Blood Glucose
Diabetes Mellitus, Type 2
/ epidemiology
Female
Follow-Up Studies
Glucose Intolerance
/ complications
Humans
Hypertension
/ complications
Longitudinal Studies
Male
Middle Aged
Obesity
/ complications
Overweight
/ complications
Poland
/ epidemiology
Prediabetic State
/ epidemiology
Prevalence
Proportional Hazards Models
Prospective Studies
Risk Factors
Rural Population
/ statistics & numerical data
Urban Population
/ statistics & numerical data
Cohort
Diabetes
IFG
Longitudinal
PURE
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
03 Jun 2020
03 Jun 2020
Historique:
received:
19
12
2019
accepted:
21
05
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
11
2020
Statut:
epublish
Résumé
Diabetes mellitus (DM) is one of the greatest challenges for public health worldwide. The aim of the study was the analysis of diabetes development in participants with normoglycemia and Impaired Fasting Glucose (IFG) in 3-year and 6-year follow-up of PURE Poland cohort study. The analysis was conducted in Polish cohort enrolled into Prospective Urban and Rural Epidemiology (PURE) Study. The following study presents results of 1330 participants that have partaken both in the baseline study, in 3-year and in the 6-year follow up. The analysis of the impact of risk factors on diabetes development was performed using multivariate Cox frailty analysis. Population Attributable Risk (PAR) was computed individually for every risk factor. Diabetes prevalence increased from 17.7% at baseline to 23.98% in 3-year- and 28.27% in 6-year follow-up. The risk of diabetes was higher in participants with obesity [HR = 5.7, 95%Cl 2,56-12,82], overweight [HR = 3.4, 95%Cl 1,56-7,54] and IFG [HR = 2.7, 95%Cl 1,87-3,85]. The risk of diabetes development was almost 2-fold higher in men than in women [HR = 1.826; 95%CI =1,24 - 2,69]. In 6 years, diabetes developed in 23.8% of participants with IFG and 7.9% of participants with normoglycemia. According to PAR, overweight and obesity accounted for 80.8%, hypertension for 67.6% and IFG for 38.3% of diabetes cases in our population. Our study reveals alarming increase in prevalence of diabetes during 6 years of observation. In our population, most diabetes cases can be attributed to overweight, obesity, hypertension and IFG. Findings add strong rationale to implement targeted preventive measures in population of high risk.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetes mellitus (DM) is one of the greatest challenges for public health worldwide. The aim of the study was the analysis of diabetes development in participants with normoglycemia and Impaired Fasting Glucose (IFG) in 3-year and 6-year follow-up of PURE Poland cohort study.
METHODS
METHODS
The analysis was conducted in Polish cohort enrolled into Prospective Urban and Rural Epidemiology (PURE) Study. The following study presents results of 1330 participants that have partaken both in the baseline study, in 3-year and in the 6-year follow up. The analysis of the impact of risk factors on diabetes development was performed using multivariate Cox frailty analysis. Population Attributable Risk (PAR) was computed individually for every risk factor.
RESULTS
RESULTS
Diabetes prevalence increased from 17.7% at baseline to 23.98% in 3-year- and 28.27% in 6-year follow-up. The risk of diabetes was higher in participants with obesity [HR = 5.7, 95%Cl 2,56-12,82], overweight [HR = 3.4, 95%Cl 1,56-7,54] and IFG [HR = 2.7, 95%Cl 1,87-3,85]. The risk of diabetes development was almost 2-fold higher in men than in women [HR = 1.826; 95%CI =1,24 - 2,69]. In 6 years, diabetes developed in 23.8% of participants with IFG and 7.9% of participants with normoglycemia. According to PAR, overweight and obesity accounted for 80.8%, hypertension for 67.6% and IFG for 38.3% of diabetes cases in our population.
CONCLUSIONS
CONCLUSIONS
Our study reveals alarming increase in prevalence of diabetes during 6 years of observation. In our population, most diabetes cases can be attributed to overweight, obesity, hypertension and IFG. Findings add strong rationale to implement targeted preventive measures in population of high risk.
Identifiants
pubmed: 32493306
doi: 10.1186/s12889-020-08970-5
pii: 10.1186/s12889-020-08970-5
pmc: PMC7268673
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
843Subventions
Organisme : Ministerstwo Nauki i Szkolnictwa Wyższego
ID : 290/W-PURE/2008/0
Organisme : Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu
ID : ST.C300.17.005
Références
Am Heart J. 2009 Jul;158(1):1-7.e1
pubmed: 19540385
Hypertens Res. 2015 Nov;38(11):783-9
pubmed: 26178151
Diabetes Care. 2018 Jul;41(7):e117-e118
pubmed: 29724784
Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S457-64
pubmed: 10993415
Public Health. 2012 Oct;126(10):813-20
pubmed: 22922043
N Engl J Med. 2001 Sep 13;345(11):790-7
pubmed: 11556298
Pol Arch Med Wewn. 2011 May;121(5):156-63
pubmed: 21610663
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):616-621
pubmed: 30641776
Am J Cardiol. 2008 Aug 15;102(4):497-8
pubmed: 18678313
Diabetes Care. 2003 Dec;26(12):3230-6
pubmed: 14633807
Diabetologia. 2019 Jan;62(1):3-16
pubmed: 30171279
Lancet. 2012 Jun 16;379(9833):2279-90
pubmed: 22683128
Circ Res. 2015 Mar 13;116(6):991-1006
pubmed: 25767285
Diabetes Res Clin Pract. 2012 Jun;96(3):271-85
pubmed: 22261096
Diabet Med. 2014 Dec;31(12):1568-71
pubmed: 24975751
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1313-1324
pubmed: 30566658
Lancet Diabetes Endocrinol. 2016 Jan;4(1):44-51
pubmed: 26575606
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
J Clin Endocrinol Metab. 2016 Oct;101(10):3740-3746
pubmed: 27490920
Ann Epidemiol. 2008 Aug;18(8):657-63
pubmed: 18652984
Arch Med Sci. 2017 Feb 1;13(1):256-259
pubmed: 28144279
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Eur Heart J. 2007 Dec;28(23):2937-43
pubmed: 17925342
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967